INVICTA (INVICTA) fundamentals
INVICTA is a listed company, part of the Healthcare sector, listed on the NSE as INVICTA (ISIN INE0XJ501010). This page carries its reported financials, balance sheet, cash flow, shareholding pattern and valuation ratios.
What INVICTA does
Invicta Diagnostic Limited is engaged in the diagnostic chain offering comprehensive radiology and pathology solutions. It offers a one-stop solution for pathology and radiology testing services such as imaging (including radiology), pathology/clinical laboratory and tele-radiology to customers under the brand name PC Diagnostics through its operational network, which consists of eight diagnostic centers and one centralized laboratory across Mumbai Metropolitan Region in the state of Maharashtra. Its test menu includes pathology tests ranging from basic biochemistry and clinical pathology which are performed at its own centers to cytogenetics and high-end molecular diagnostic tests which are outsourced to larger reference laboratories, and radiology tests ranging from basic echocardiograms, X-rays and ultrasounds to advanced radiology tests including computerized tomography (CT) scans, magnetic resonance imaging (MRI) scans and advanced positron emission tomography CT.
Valuation and market data
| Last close | ₹68.00 |
|---|---|
| Market capitalisation | ₹68 crore |
| Enterprise value | ₹46 crore |
| P/E (TTM) | 0.00 |
| Price to book | 1.38 |
| Price to sales (TTM) | 0.00 |
| Book value per share | ₹49.37 |
| Dividend yield | 0.00% |
| Sector | Healthcare |
| Industry | — |
Annual results
| Period | Revenue | Profit before tax | Net profit | EPS |
|---|---|---|---|---|
| Mar 2026 | ₹21 crore | ₹7 crore | ₹6 crore | 5.56 |
| Mar 2025 | ₹18 crore | ₹7 crore | ₹5 crore | 6.39 |
| Mar 2024 | ₹5 crore | ₹2 crore | ₹2 crore | 182.49 |
Figures are as reported (standalone), in ₹ crore.
Shareholding pattern
As of Mar 2026:
| Promoters | 66.7% |
|---|---|
| Foreign institutions (FII) | 4.2% |
| Mutual funds | 0.0% |
| Other domestic institutions | 4.3% |
| Retail and others | 24.8% |
More on BreakPoint
FundaX company research covers every listed company with reported financials. BreakPoint Pro adds the BreakPoint iQ score, the screener and the multibagger board.
Data is sourced from exchange filings and vendor feeds and is for research, not investment advice. Figures can be restated by the company after publication.